首頁 > 市場調查報告書 > 製藥

開發平台分析

市場調查報告書

商品編碼

1550617

標籤先天性黑蒙市場：依治療類型、依目標基因、依最終用戶、按地區

Leber Congenital Amaurosis Market, By Treatment Type, By Target Gene, By End User, By Geography

出版日期: 2024年08月19日 | 出版商:

Coherent Market Insights | 英文 140 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計2024年全球先天性黑蒙市場規模為12.3億美元，預計2031年將達16.8億美元，2024年至2031年複合年成長率為4.5%。

報告範圍		報告詳情
基準年	2023年	2024年市場規模	12.3億美元
實際資料	2019年至2023年	預測期	從2024年到2031年
預測 2024-2031 年複合年成長率：	4.50%	2031年價值預測	16.8億美元

圖：2024 年各地區標示先天性黑蒙市場佔有率(%)

萊伯先天性黑蒙（LCA）是一群遺傳性視網膜疾病，從出生起就會導致嚴重的視力障礙。其特徵是視力下降和眼球震顫，並可能導致失明。 LCA 通常是由控制光感受器發育和視網膜色素上皮功能的基因突變引起的。由於感光細胞進行性退化，患者會遭受嚴重的視力喪失和失明。目前，LCA 尚無有效治療方法。然而，基因療法和視網膜假體裝置有可能改善受影響個體的視力。由於新治療劑和設備的開發，LCA 的全球市場預計在未來幾年將顯著成長。

市場動態：

全球標籤先天性黑蒙市場受到多種因素的推動，包括遺傳性視網膜疾病發病率的上升、基因治療產品和視網膜假體設備管道的擴大以及政府和非營利組織研究經費的增加，預計將經歷高速成長。然而，目前，缺乏核准的治療方案以及基因和細胞治療的高成本可能會阻礙市場成長。從積極的一面來看，正在進行的評估基因療法的臨床試驗和提高疾病管理意識正在為市場創造重大機會。

本研究的主要特點

該報告對全球標籤先天性黑蒙市場進行了詳細分析，並提供了以2023年為基準年的預測期（2024-2031年）的市場規模（十億美元）和年複合成長率（CAGR%）。

它還揭示了各個細分市場的潛在商機，並說明了該市場有吸引力的投資提案矩陣。

它還提供了對市場促進因素、阻礙因素、機會、新產品發布和核准、市場趨勢、主要企業採取的競爭策略等的重要見解。

本研究涵蓋的主要企業包括 Spark Therapeutics、MeiraGTx Holdings plc、AGTC 和 ProQR Therapeutics NV。

該報告的見解使負責人和公司經營團隊能夠就未來的產品發布、升級、市場擴張和行銷策略做出明智的決策。

全球標籤先天性黑蒙市場報告迎合了該行業的各個相關人員，如投資者、供應商、產品製造商、經銷商、新進入者和財務分析師。

透過用於分析全球標籤先天性黑蒙市場的各種策略矩陣，將促進相關人員的決策。

Report Coverage	Report Details
Base Year:	2023	Market Size in 2024:	US$ 1.23 Bn
Historical Data for:	2019 To 2023	Forecast Period:	2024 To 2031
Forecast Period 2024 to 2031 CAGR:	4.50%	2031 Value Projection:	US$ 1.68 Bn

Leber congenital amaurosis (LCA) is a group of inherited retinal diseases causing severe visual impairment from birth. It is characterized by poor vision, nystagmus, and potentially blindness. LCA is typically caused due to mutations in genes responsible for photoreceptor development and retinal pigment epithelium function. As a result of progressive degeneration of photoreceptor cells, patients suffer from severe visual loss and blindness. Currently, there are no effective treatment options for LCA. However, gene therapy and retinal prosthetic devices hold promise to improve vision in affected individuals. The global LCA market is poised to grow significantly over the coming years driven by the development of novel therapeutics and devices.

Market Dynamics:

The global Leber congenital amaurosis market is projected to witness high growth over the next decade owing to several factors such as rising incidence of genetic retinal disorders, growing pipeline of gene therapy products and retinal prosthetic devices, and increasing research funding from government and non-profit organizations. However, lack of approved treatment options currently along with high cost of gene and cell-based therapies can hamper market growth. On the positive side, ongoing clinical trials evaluating gene therapies and increasing awareness about disease management provide significant opportunities in the market.

Key features of the study:

This report provides in-depth analysis of the global Leber congenital amaurosis market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, and competitive strategies adopted by key players

Key companies covered as part of this study include Spark Therapeutics, MeiraGTx Holdings plc, AGTC, ProQR Therapeutics N.V.

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

Global Leber congenital amaurosis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Leber congenital amaurosis market

Detailed Segmentation-

By Treatment Type Insights (Revenue, USD Bn, 2019 - 2031)
- Gene Therapy
- Pharmaceutical Drugs
- Retinal Prosthesis
- Assistive Devices
- Others
By Target Gene Insights (Revenue, USD Bn, 2019 - 2031)
- RPE65
- GUCY2D
- AIPL1
- RPGRIP1
- CEP290
- Other Genes
By End-user Insights (Revenue, USD Bn, 2019 - 2031)
- Hospitals
- Specialized Eye Clinics
- Ophthalmology Research Centers
- Home Care Settings
- Others
By Regional Insights (Revenue, USD Bn, 2019 - 2031)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- Novartis
- Biogen
- Spark Therapeutics
- GenSight Biologics
- Roche
- AbbVie
- Regeneron Pharmaceuticals
- Pfizer
- Astellas Pharma
- Santen Pharmaceutical
- Orphan Biovitrum
- Apellis Pharmaceuticals
- Gilead Sciences
- Eyenovia
- Avexis
- Regenxbio
- Horizon Therapeutics
- Aerie Pharmaceuticals
- Ophthotech Corporation
- Aldeyra Therapeutics

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Leber Congenital Amaurosis Market, By Treatment Type
- Global Leber Congenital Amaurosis Market, By Target Gene
- Global Leber Congenital Amaurosis Market, By End User
- Global Leber Congenital Amaurosis Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Impact Analysis
Key Highlights
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario

4. Global Leber Congenital Amaurosis Market, By Treatment Type, 2024-2031, (USD Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Gene Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Pharmaceutical Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Retinal Prosthesis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Assistive Devices
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

5. Global Leber Congenital Amaurosis Market, By Target Gene, 2024-2031, (USD Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
RPE65
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
GUCY2D
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
AIPL1
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
RPGRIP1
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
CEP290
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Other Genes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Global Leber Congenital Amaurosis Market, By End-User, 2024-2031, (USD Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Specialized Eye Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Ophthalmology Research Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Home Care Settings
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Global Leber Congenital Amaurosis Market, By Region, 2019 - 2031, Value (USD Bn)

Introduction
- Market Share (%) Analysis, 2024,2027 & 2031, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2019 - 2031, Value (USD Bn)
- Regional Trends
  - North America
- Introduction
- Market Size and Forecast, By Treatment Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Target Gene, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By End-User, 2019 - 2031, Value (USD Bn)
U.S.
Canada
Latin America
- Introduction
- Market Size and Forecast, By Treatment Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Target Gene, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By End-User, 2019 - 2031, Value (USD Bn)
Brazil
Argentina
Mexico
Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Treatment Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Target Gene, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By End-User, 2019 - 2031, Value (USD Bn)
Germany
U.K.
Spain
France
Italy
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Treatment Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Target Gene, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By End-User, 2019 - 2031, Value (USD Bn)
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Treatment Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Target Gene, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By End-User, 2019 - 2031, Value (USD Bn)
GCC Countries
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Treatment Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Target Gene, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By End-User, 2019 - 2031, Value (USD Bn)
South Africa
North Africa
Central Africa

8. Competitive Landscape

Novartis
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Biogen
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Spark Therapeutics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
GenSight Biologics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Roche
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
AbbVie
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Regeneron Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Pfizer
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Astellas Pharma
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Santen Pharmaceutical
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Orphan Biovitrum
Apellis Pharmaceuticals
Gilead Sciences
Eyenovia
Avexis
Regenxbio
Horizon Therapeutics
Aerie Pharmaceuticals
Ophthotech Corporation
Aldeyra Therapeutics

9. Analyst Recommendations

Wheel of Fortune
Analyst View
Coherent Opportunity Map

10. References and Research Methodology

References
Research Methodology
About us

02-2729-4219

+886-2-2729-4219

License/價格

相關商品

冠狀動脈疾病市場：按類型、最終用戶分類 - 全球預測 2025-2030

Cat 過敏管道市場：按產品類型、治療方法、過敏類型、患者人口統計、分銷管道、最終用戶和配方 - 2025-2030 年全球預測

標籤先天性黑蒙市場報告：2030 年趨勢、預測與競爭分析

FAQ

標籤先天性黑蒙市場：依治療類型、依目標基因、依最終用戶、按地區